Last updated 7 days ago

Focal Extracorporeal Shock Wave Therapy With Two Different Dosing Regimens for Chronic Low Back Pain

60 patients around the world
Available in Mexico
Chronic mechanical low back pain is a common musculoskeletal condition that leads to functional disability and diminished quality of life. While focal extracorporeal shock wave therapy (F-ESWT) has emerged as a non-invasive treatment option to promote tissue regeneration and modulate inflammation, clinical protocols lack precise standardization regarding energy density and session distribution. This randomized, double-blind clinical trial aims to analyze the clinical effects of two specific dosing regimens of F-ESWT. Eligible participants from the Physical Medicine and Rehabilitation Service will be randomly allocated to either Group A or Group B. Both groups will undergo targeted applications to the lumbar region using predefined therapeutic parameters detailed in the protocol. Clinical evaluations will be performed at baseline and during post-treatment follow-up periods. Pain intensity, functional disability, and localized mobility will be measured using validated clinical tools to define which dosing scheme optimizes short-term and mid-term patient recovery.
Armando Tonatiuh Avila Garcia
1Research sites
60Patients around the world

This study is for people with

Low Back Pain

Requirements for the patient

To 80 Years
All Gender

Medical requirements

Individuals of both sexes.
Age between 18 and 65 years.
Clinical diagnosis of mechanical chronic low back pain (cLBP), defined as pain localized between the lower costal margin and the gluteal fold, with at least 12 weeks of evolution.
Lumbar pain intensity of at least 5/10 on the Numeric Pain Rating Scale (NPRS).
Predominantly mechanical pain, exacerbated by activities such as prolonged standing, trunk movements, extension, or lumbar rotation, and without clinical data of predominant radicular pain.
Plain radiograph of the lumbar spine available as part of the baseline evaluation.
Ability to attend all 4 treatment sessions and subsequent follow-up evaluations.
Signed informed consent form previously approved by the Institutional Review Board / Research Ethics Committee.
Low back pain of probable non-mechanical origin or secondary to a specific cause that substantially modifies clinical management.
Clinical data of predominant lumbar radiculopathy, including pain radiating below the knee with a dermatomal distribution, focal motor deficit, objective sensory alterations, or compatible reflex changes.
Diagnosis or suspicion of cauda equina syndrome.
History of previous lumbar spine surgery.
Current vertebral fracture or recent history of lumbar fracture.
Spondylolisthesis grade II or higher.
Significant structural scoliosis or severe lumbar deformity that prevents treatment standardization.
Suspicion or evidence of a tumor, infection, spondylodiscitis, or axial inflammatory disease.
Severe clinically documented osteoporosis or history of vertebral fragility fracture.
Pregnancy or lactation.
Coagulation disorder, use of anticoagulants at therapeutic doses, or a hemorrhagic condition that increases procedure risk.
Previous epidural infiltration, facet block, radiofrequency, or other lumbar interventional procedure within a recent period defined by the protocol.
Current treatment with another physical rehabilitation modality or instrumental therapy directed at low back pain, if it cannot be suspended during the intervention period.
Current use of nonsteroidal anti-inflammatory drugs (NSAIDs) that the patient cannot suspend according to the study indications.
Concomitant neurological, rheumatological, oncological, or musculoskeletal disease that significantly interferes with pain or disability evaluation.
Cognitive impairment, decompensated psychiatric disorder, or any condition that prevents understanding instructions, answering questionnaires, or completing follow-up.

Sites

Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde - Guadalajara
Coronel Calderon 777, Guadalajara, Jalisco
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy